



RESEARCH ARTICLE

INHIBITION OF COX-2 ENZYME BY THE VARIOUS EXTRACTS OF *LEUCAS ASPERA* FOR ANTI-INFLAMMATORY ACTIVITY IN ALBINO RAT

<sup>1</sup>Sudhakara Reddy, M., <sup>2</sup>Udaykiran, V., <sup>\*,3</sup>Sivasankar, R., <sup>4</sup>Muniya Naik, M. and <sup>5</sup>Subahan, M.

<sup>1</sup>Department of Zoology, Loyola Degree College, Pulivendula, A.P.

<sup>2,3,5</sup>Department of Zoology, S.V.University, Tirupati, A.P.

<sup>4</sup>S.G.Govt.Degree College, Piler, A.P.

ARTICLE INFO

Article History:

Received 13<sup>th</sup> April, 2017  
Received in revised form  
09<sup>th</sup> May, 2017  
Accepted 29<sup>th</sup> June, 2017  
Published online 26<sup>th</sup> July, 2017

Key words:

*Leucas aspera*,  
Anti-inflammatory activities,  
COX-2 enzyme,  
Albino rat.

ABSTRACT

The present investigation was aimed at evaluating the ethanol extract of leaves of *Leucas aspera* has been found to possess antibacterial activity and Anti-inflammatory Activity, Cyclooxygenase (COX), also called Prostaglandin H Synthase or (PGHS) is a bifunctional enzyme exhibiting both cyclooxygenase and peroxidase activities. COX-2 products are responsible for modulating dynamic processes such as inflammation. COX-2 is the true molecular target for developing anti-inflammatory and analgesic agents. Pathogen free, Wistar strain albino rats were used in the present study, In order to study the anti-inflammatory activity of four extracts of *Leucas aspera* viz., petroleum ether, chloroform, ethanol, water extracts .whereas the purified fraction F<sub>5</sub> of ethanol extract were screened for their *in vivo* COX-2 enzyme inhibition assay, And the purified fraction (F<sub>5</sub>) of ethanol extract it is essential to carry out the COX enzyme inhibition assay. The fraction F<sub>5</sub> of ethanol extract of *L. aspera* has shown significant COX-2 enzyme inhibition activity. The chemical molecule present in the fraction F<sub>5</sub> is responsible for the inhibition of COX-2 enzyme present in the blood plasma of experimental rats. The present study reveals that ethanolic extract of *leucas aspera* sprenge showed significant anti-inflammatory activity and COX- II enzyme inhibition studies.

Copyright©2017, Sudhakara Reddy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Sudhakara Reddy, M., Udaykiran, V., Sivasankar, R., Muniya Naik, M. and Subahan, M. 2017. "Inhibition of cox-2 enzyme by the various extracts of *Leucas aspera* for anti-inflammatory activity in albino rat", *International Journal of Current Research*, 9, (07), 53870-53874.

INTRODUCTION

Since thousands of years, humans have relied almost entirely on plants to treat all manners of illness; from minor problems to life-threatening diseases (Chevallier, 2001). About 80% of the people still depend largely on traditional plant derived drugs for their primary health care (Akerle, 1993). In the developing countries, the herbal medicine is deep rooted even today. Traditional practitioners play important role in their communities particularly with regard to common ailments and chronic disorders (Bannerman, 1982). The discovery of the penicillin from microbes and isolation of antimalarial alkaloids, cardiogenic glycosides, anticancer agents etc., from plants are the significant evidences for importance of natural products for the benefit of mankind. *Leucas aspera* Spreng (Labiatae) is an annual herb found throughout India as a weed in cultivated fields, waste lands and roadsides. Its leaves, roots, stalks, young shoots and flowers have been used for wide range of medicinal properties (Kirtikar and Basu, 1991). Literature survey revealed that ethanol extract of leaves of

*Leucas aspera* has been found to possess antibacterial activity and Anti-inflammatory Activity (Shirazi, 1947), Anti-inflammatory agents may thus act by interfering with any one of several mechanisms including immunologic mechanisms such as antibody production, antigen-antibody complexation, activation of complement, cellular activities such as phagocytosis, formation and release of chemical mediators of inflammation and stabilization of lysosomal membranes. For many years COX was thought to be a single enzyme. The 1990s saw a new dawn in this area with biological studies demonstrating increased COX activity in a variety of cells after exposure to endotoxin (Fuj et al., 1990; Masferrer et al., 1990), proinflammatory cytokines (Raz et al., 1989; Risti Maci et al., 1994) growth factors hormones (Sirois and Richard, 1993); tumor promoters (Kujubu et al., 1991). This activity required new protein synthesis and was inhibitable by corticosteroids. These data suggested the existence of a second novel COX isoenzyme synthesised *de novo* in the presence of inflammatory stimuli and the concept of constitutive COX-1 and inducible COX-2. COX-1 products are responsible for normal homeostasis i.e. the house keeping functions whereas COX-2 products are responsible for modulating dynamic processes such as inflammation. NSAIDs inhibit the two


\*Corresponding author: Sivasankar, R.  
Department of Zoology, S.V.University, Tirupati, A.P.

isoforms to different extents and this feature accounts for their shared therapeutic properties and side effects (Vane *et al.*, 1998).

### Cyclooxygenase isoenzymes

Cyclooxygenase enzyme also known as prostaglandin endoperoxide H synthase. (PGHS) are bifunctional heme containing proteins with both cyclooxygenase and peroxidase activities (Needleman *et al.*, 1986; Dewitt, DL 1991). Because the cyclooxygenase activity catalyzes the first step in the biosynthesis of prostaglandin endoperoxides the protein is frequently referred to by the name of this activity (COX). COX catalyzes the conversion of arachidonic acid to prostaglandin  $\text{PGH}_2$  (Chart 1), the later being the essential precursor of prostaglandins, thromboxane and prostacyclin. In both COX-1 and COX-2, Tyr 385 is the catalytic active site. Arachidonic acid lies in a bent conformation with its C-13 in the vicinity of Tyr 385 and the carboxylate group interacting with Arg 120. Initially the heme group of the enzyme is oxidized at the peroxidase active site. The oxidized heme group of the enzyme is oxidized at the peroxidase active site. The oxidized heme group then oxidizes the Try 385 and forms the tyrosyl radical, which abstracts the 13S-hydrogen from the arachidonic acid and allows the subsequent insertion of molecular oxygen at C-11. The resulting 11-peroxyl radical initiates cyclization events that produces, 9,11-endoperoxide into which another molecule of oxygen inserts to form 15-peroxyl radical. The donation of a hydrogen atom back to the substrate creates  $\text{PGG}_2$  (Picot *et al.*, 1994).  $\text{PGG}_2$  undergoes a two electron reduction at the peroxidase active site to form  $\text{PGH}_2$  (Rowlinson *et al.*, 2000).

**Chart-1: The prostanoid biosynthetic pathway (Smith *et al.*, 1996)**



NSAIDs compete directly with arachidonate for binding to the cyclooxygenase active site and inhibit COX activity by excluding arachidonate from the active site.

### Physicochemical properties

Cyclooxygenase-1 and 2 are homodimeric, heme containing, glycosylated integral membrane proteins with two catalytic sites (Jouzeau *et al.*, 1997). Both COX isoforms are seen in most mammals. In humans, the COX-1 gene is on chromosome 9 and the COX-2 gene is on chromosome 1 (Bjorkman, 1998). Genetic analysis shows that for a given COX isoform there is approximately 90% identity between species, but there is only 60% homology between the two COXs at the nucleic acid and amino acid levels. The signal peptide for COX-1 is seven residues longer than that of COX-2. COX-1 contains a sequence of 17 amino acids in its amino terminus that is not present in COX-2, while COX-2 has an additional insert of 18 amino acids in its carboxyl terminus (Jouzeau *et al.*, 1997).

Amino acid residue	COX-1	COX-2
434	Ile	Val
513	His	Arg
516	Ser	Ala
523	Ile	Val

**Source:** The amino acids thought to be important for catalysis are conserved. However, there are some differences in the active site (De Witt *et al.*, 1993).

The presence of Val 523 in COX-2 instead of Ile in COX-1 plays a crucial role in selectivity of NSAIDs for COX-2 enzyme (Kurumbail *et al.*, 1996). The two isoenzymes have about same affinity ( $K_m$ ) and capacity ( $V_{max}$ ) to convert arachidonic acid to  $\text{PGH}_2$  (Percival *et al.*, 1994). COX-2 is also able to metabolize C18 and C20:3 fatty acids as substrates, while COX-1 is mainly restricted to arachidonic acid (C20:4).

### Regulation and localization

The two COX isoenzymes are distinctly regulated at both transcriptional and post transcriptional level (Smith and Dewitt, 1996; Herschmann, 1996; Williams and Dusois, 1996). The transcripts of COX-1 and COX-2 differ significantly in size. The transcript of COX-2 gene is prone to degrade quickly. COX-2 is undetectable in most tissue but can be rapidly induced in fibroblasts, ovarian follicles, endothelial cells, monocytes in response to growth factors, tumor promoters, hormones, bacterial endotoxins and cytokines and hence called inducible. Anti-inflammatory steroids inhibit COX-2 expression. COX-1 on the other hand is present in most of the tissues and hence is called constitutive. This concept is however an oversimplification, as COX-2 is constitutively expressed in brain, testes, tracheal epithelia, and macula densa in kidney, while COX-1 level changes during development and its expression can be down regulated in endothelial cells and upregulated in mast cells (Smith and Dewitt, 1996).

## MATERIALS AND METHODS

### Collection of the Plant Material

The fresh whole plant of *Leucas aspera* (3 kg) was collected in the month of July and August in and around Sri Venkateswara University campus and authenticated at the Herbarium (Voucher No. 210), Department of Botany, S.V. University,

Tirupati. Collected plants were immediately sprayed with alcohol to cease the enzymatic degradation of secondary metabolites. They were chopped into small fragments, thick stem, roots, twigs and other woody parts were chopped into 1" to 2" pieces and split longitudinally into several sections to enable early drying under shade. Chopping fresh plant materials at once after collection hastens drying and advantages on reduction in bulk and drying speed. The plant was kept under shade for drying for about 7 days.

### Procurement of chemicals

Lipopolysaccharide (LPS) and N,N,N,N-tetramethyl p-phenylenediamine (TMPD) were purchased from Sigma chemical Co. Ltd. Enzyme inhibition assay kit was obtained from Assay Designs, Inc. (Ann Arbor, MI, USA). Recombinant human COX-2 was a generous gift from Shozo Yamamoto (School of Medicine, University of Tokushima, Japan).

### Animals

Pathogen free, Healthy wistar strain albino rats were selected in the present study, the usage of animals was approved by the Institutional Animal Ethics Committee. The rats were housed in clean polypropylene cages under hygienic conditions with photoperiod of 12 hours light and 12 hours dark. The rats were fed with standard laboratory chow (Hindustan lever Ltd, Mumbai) and water *ad libitum*.

### Present experimental work

Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances involved in several physiological processes and also in pathological conditions such as inflammation. It has been well known for 10 years that this enzyme exists under two forms, a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional non-steroidal anti-inflammatory drugs NSAIDs. Observations were made that COX-1 was mainly involved in homeostatic processes, while the COX-2 expression was associated with pathological conditions leading to the development of COX-2 selective inhibitors. Several methods have been reported for the evaluation of the COX-1 and COX-2 inhibitory potency and selectivity of conventional or COX-2 selective NSAIDs. In this study, we evaluated the COXs inhibitory profile of both conventional NSAIDs and COX-2 selective inhibitors using two different *in vitro* methods; the first test was performed using purified enzymes while the second method consisted of a whole blood assay (Fuj *et al.*, 1990). Cyclooxygenase (COX), also called Prostaglandin H Synthase or (PGHS) is a bifunctional enzyme exhibiting both cyclooxygenase and peroxidase activities. The cyclooxygenase component converts arachidonic acid to a hydroperoxy endoperoxide (Prostaglandin G PGG and the peroxidase component reduces the endoperoxide to the corresponding alcohol (Prostaglandin H PGH the precursor of prostaglandins, thromboxanes, and prostacyclins (Hamberg and Samuelsson, 1973). It is now well established that there are two distinct isoforms of cyclooxygenase. Cyclooxygenase-1 (COX-1) is constitutively expressed in a variety of cell types and is involved in normal cellular homeostasis. A variety of mitogenic stimuli such as phorbol esters, lipopolysaccharides and cytokines, lead to the induced expression of a second isoform of COX, cyclooxygenase-2 (COX). COX-2 is

responsible for the biosynthesis of prostaglandins under acute inflammatory conditions (Xie *et al.*, 1991). The inducible COX-2 is believed to be the target enzyme for the anti-inflammatory activity of nonsteroidal anti-inflammatory drugs. The Colorimetric COX (ovine) Inhibitor Screening Assay utilizes the peroxidase component of cyclooxygenases. The peroxidase activity is assayed colorimetrically by monitoring the appearance of oxidized N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) at 590 nm (Kulmacz and Lands, 1983). Inhibition of COX activity by a variety of selective and non-selective inhibitors, showed potencies similar to those observed with other *in vitro* methods. The Colorimetric COX (ovine) inhibitor screening assay includes both ovine COX-1 and COX-2 enzymes in order to screen isoenzyme specific inhibitors. This COX assay is a time saving tool for screening vast numbers of inhibitors. In the present work, we have screened the various extracts of *Leucas aspera* and semipurified fraction (F<sub>5</sub>) of ethanol extract of *L. aspera*.

### Treatment schedule

The assay was carried out as previously described (Brideau *et al.*, 1996) with little modification. Albino rats of either sex weighing between 150-200 g maintained on standard pellet diet and water were used for the study and they were fasted overnight. These animals were separated into seven groups of five animals each. Group first received 5% gum acacia solution and served as a control. Group second received celecoxib at a dose of 50 mg/kg body weight and used as reference standard. Groups three, four, five and six received petroleum ether, chloroform, ethanol and water extracts of *Leucas aspera*, respectively at a dose of 400 mg/kg body weight. Group seven received fraction F<sub>5</sub> of ethanol extract of *Leucas aspera* at a dose of 400 mg/kg body weight. All the treatments were given orally one hour before their sacrifice. All the experimental animals were sacrificed and whole blood was collected by venipuncture into heparinised tubes. 1 ml aliquot of whole blood was incubated both in presence and absence of Lipopolysaccharide (LPS) obtained from *E. coli* in a concentration of 10 µl-100 µl. The contribution of platelet COX was suppressed by the addition of 200 µm of aspirin. After incubation, the plasma from the samples was separated by centrifugation of the whole blood samples at 1000 x g for 10-15 min. The optical density of the resulting plasma was recorded by using spectrophotometer at a wavelength of 611 nm. The UV-visible spectrum of phycocyanobilin was recorded between 280-500 nm in methanol 2% HCl and the concentration was estimated at 374 nm using extinction coefficient of 47.900 M<sup>-1</sup> cm<sup>-1</sup>. The results obtained were calculated as A<sub>611</sub>/0.00826 µm<sup>-1</sup> x 0.21 / 0.01 / 2\* n mole/ml (U/ml) (\*It takes 2 molecules of TMPD to reduce PGG<sub>2</sub> to PGH<sub>2</sub>). The data so obtained was subjected to statistical analysis and are listed in Table 1.

### Statistical analysis

Statistical analysis has been carried out using ANOVA followed by Dunnett's (t) test. The data was analyzed for the significance and the results were presented with the P-value.

## RESULTS AND DISCUSSION

Previous report (Saundane, 2000) on anti-inflammatory activity of *L. aspera* showed good anti-inflammatory activity of crude ethanolic extract. Srinivas *et al.* also reported that the dried

**Table 1. Evaluation of cyclooxygenase-2 activity in whole blood (LPS method) UNITS/ML**

	Control	Celecoxib	Pet. Ether extract	Chloroform extract	Alcohol extract	Water extract	Fraction F <sub>5</sub>
	10.58	65.05	20.59	33.3	16.27	21.35	58.72
	14.3	54.25	15.7	28.25	35.84	30.5	36.35
	16.2	56.25	15.3	29.5	40.67	26.69	54.4
	21.33	57.25	21.06	28.95	21.58	27.12	42.25
	14.28	50.09	17.44	32.47	31.29	28.01	58.84
	11.38	61.15	14.05	29.98	39.92	29.41	48.24
Mean	15.33	56.18	17.24	30.59	30.93	26.18	49.82
±SEM	1.734	2.613*	1.220	1.026	4.091*	1.700	3.754*

Data are expressed in mean ± SEM (Units/ml).

P<0.01 when compared with control.

ANOVA followed by Dunnett's (t) test.

Drugs are prepared in suspension with 5% gum acacia given by per orally.

leaves of *L. aspera* possessed significant anti-inflammatory activity respectively. The four extracts of *Leucas aspera* viz., petroleum ether, chloroform, ethanol, water extracts and the purified fraction F<sub>5</sub> of ethanol extract were screened for their *in vivo* COX-2 enzyme inhibition assay by whole blood plasma method (Brideau *et al.*, 1996) using albino rats. Fraction F<sub>5</sub> of ethanol extract showed significant inhibition activity compared to control. The inhibition activity of chloroform, ethanol and water extracts is moderate and that of petroleum ether extract is nearly as that of control group (Table.1) As described earlier COX enzyme heads complex biosynthetic cascade that results in the conversion of polyunsaturated fatty acids to prostaglandins and thromboxane which are responsible for many physiological effects and pathophysiological responses. The synthesis of prostaglandins during the inflammation is more and the inhibition of COX enzyme for the benefit of management of inflammation and pain is well established and many agents are already in the clinical practice for the same purpose (X de Leval *et al.*, 2001). In order to study the anti-inflammatory activity of four extracts of *Leucas aspera* and the purified fraction (F<sub>5</sub>) (Table.1) of ethanol extract it is essential to carryout the COX enzyme inhibition assay. The fraction F<sub>5</sub> of ethanol extract of *L. aspera* has shown significant COX-2 enzyme inhibition activity. The chemical molecule present in the fraction F<sub>5</sub> is responsible for the inhibition of COX-2 enzyme present in the blood plasma of experimental rats. Similarly the extracts of *L. aspera* may contain chemical moieties which show moderate or least activity. In the present study the anti-inflammatory activity four extracts of *Leucas aspera*, it is essential to carryout the COX enzyme inhibition assay shown in TABLE 1. The chemical molecule(s) present in them are responsible for the inhibition of COX-2 enzyme that present in the blood plasma of experimental rats (Kalaskar *et al.*, 2010).

## Conclusion

Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances involved in several physiological processes and also in pathological conditions such as inflammation. Hence, the present investigation is taken up to study the anti-inflammatory activity of various solvent extracts of *leucas aspera* speng. The present study reveals that ethanolic extract of *leucas aspera* speng showed significant anti-inflammatory activity and COX- II enzyme inhibition studies.

## Acknowledgement

Authors are thankful to Ex-Principal, Prof. K.Jayantha Rao, (S.V.U.C.S) for their constant Encouragement, and also

express deep sense of gratitude to Department of Zoology, Sri Venkateswara University. Tirupathi (A.P) for providing laboratory facilities to carry out this work and cooperation.

## REFERENCES

- Akerele, O. 1993. Nature's medicinal bounty: Don't throw it. *World Health Forum*, 14, 390-395.
- Bannerman, R.H. 1982. *Traditional medicine in modern health care. World Health Forum*, 3, 8-13.
- Bjorkman, D.J. 1998. *Amer. J. Med.*, 105(1B), 8-125.
- Brideau, C., Kargman, S., Liu, S., Dallob, A.L., Ehrich, E.W., Rodger, I.W., and Chan, C.C. 1996. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors, *Inflamm.Res.* 45 68-74.
- DeWitt DL. 1991. Prostaglandin endoperoxide synthase: regulation of enzyme expression. *Biochim Biophys Acta*; 1083:121-134.
- Dewitt, D 1983. *Biochim. Biophys. Acta*, 108, 121-134.
- Dewitt, D.L., Meade, E & Smith, W.L 1993. *Amer. J. Med.*, 95, 405-445.
- Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. 1990. The induction and suppression of prostaglandin H<sub>2</sub> synthase (cyclooxygenase) in human monocytes. *J Biol Chem.* Oct 5;265(28):16737-16740.
- Hamberg M. and Samuelsson B. 1973. Detection and isolation of an endoperoxide intermediate in ... *Proc Natl Acad Sci U S A.* Mar;70(3):899-903.
- Herschmann, H.R. 1996. Prostaglandin synthase 2. *Biochim. Biophys. Acta.*, 1299(1), 125-140.
- Jouzeau JY, Terlain B, Abid A, Nédélec E, Netter P. 1997. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. *Drugs*, Apr;53(4):563-582.
- Kalaskar G.P., M.Girisha, M.G.Purohit, B.S.Thippeswamy, B.M.Patil, March, 2010. In vivo assay of various extracts of *Leucas aspera* speng for anti-inflammatory activity., *NPAIJ*, 6(1) Vol.6 issue.1
- Kirtikar, K.R & Basu, B.D 1991. *Indian Medicinal Plants*, Vol. III, Lalit Mohan Basu, Dehradun, India, p. 2019.
- Kujubu D. A., Reddy S. T., Fletcher B. S., and Henchman H. R. 1993. Expression of the protein product of the prostaglandin synthase- 2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. *J. Bid. Chem.*, 268, 5425-5430.
- Kulmacz, R.J & Lands, W.E.M. 1983. Requirements for hydroperoxide by the cyclooxygenase and peroxidase activities of prostaglandin H synthase. *Prostaglandins*, 25(4); 531-540.
- Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K & Isakson, P.C. 1996. Structural basis for selective

- inhibition of cyclooxygenase-2 by anti-inflammatory agents. *Nature*, 19-26; 384, (6610) 644-648.
- Masferrer JL, Zweifel BS, Seibert K, Needleman P. 1990. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. *J Clin Invest.*, Oct;86(4):1375-1379.
- Needleman, P., Turk, J., Jakshick, B.A., Morrison, A.R & Lefkowitz, J.B. 1986. Arachidonic acid metabolism. *Annu. Rev. Biochem.*, 55, 69-102.
- Picot D., Loll, P.J & Garavito, M.R 1994. The X-ray crystal structure of the membrane protein prostaglandin H<sub>2</sub> synthase-1. *Nature*, 367, 243-249.
- Raz A, Wyche A, Needleman P. 1989. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. *Proc Natl Acad Sci U S A.* Mar; 86(5):1657-1661
- Ristimäki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. 1994. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. *J Biol Chem.*, Apr 22;269(16):11769-11775.
- Rowlinson, S.W. Crews, B.C., Goodwin, D.C., Schneider, C., Gierse, J.K & Marnett, L.J 2000. Spatial requirements for 15- $\omega$ -hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2 why acetylated COX -1 does not synthesize 15 - $\omega$ -hete. *J. Biol. Chem.*, 276, 6586-91
- Saundane AR, Hidayat Ull KM, Satyanarayan ND. 2000. Antiinflammatory activity and analgesic activity of various extracts of *Leucas aspera* Spreng. *Ind J Pharm Sci.*, 62:144-6
- Shiraji, A.M. 1947. Studies on *Leucas aspera* *Indian J. Pharm.*, 19: 116-117.
- Sirois, J & JoAnne S, Richards, J.S 1993. Transcriptional Regulation of the Rat Prostaglandin Endoperoxide Synthase 2 Gene in Granulosa Cells. *J. Biol. Chem.*, 268, 21931-21938.
- Smith WL, Garavito RM, DeWitt DL. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. *J Biol Chem.*, Dec 27;271(52):33157-33160.
- Smith, W.L & DeWitt, D.L. 1996. Prostaglandin endoperoxide H synthases-1 and -2. *Adv. Immunol.*, 62, 167-215.
- Srinivas K, Rao MEB, Rao SS. 2000. Antiinflammatory activity of *Heliotropium Indicum* Linn. and *Leucas aspera* Spreng. in albino rats. *Indian J Pharmacol.*, 32:37-8.
- Vane JR. 1998. Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. *Am J Med.*, 104:25-85.
- Williams, C.S & Dubois, R.N. 1996. Prostaglandin endoperoxide synthase: why two isoforms? *Am. J. Physiol.*, 270, G393-400.
- X-de leval, J., Delarge, P., Devel, P., Nevel, C., Michaux, B., Masereel, B., Pirotte, J.L., David, Y & Henrotin, J. 2001. Dogne Prostaglandins, *Leukotrienes and Essential Fatty Acids*, 64, 211-216.
- Xie, W., Chipman, I.G & Robertson, D.I. 1991. Expression of a mitogen responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc. Natl. Acad. Sci.*, USA 88, 2692-2696.

\*\*\*\*\*